What You Should Know:– Helix, a leader in population genomics and precision health, today announced the launch of a new clinico-genomic dataset comprising over 15,000 patients treated with glucagon-like peptide-1 (GLP-1) agonists.– These medications, which include semaglutide, tirzepatide, and liraglutide, are increasingly used to treat type 2 diabetes, obesity, and other metabolic conditions.GLP-1 Agonist Virtual RegistryThis research-ready dataset, known as a Virtual Registry, was built as part of the Helix Research Network (HRN). It combines comprehensive genomic information with longitudinal electronic health record (EHR) data, providing researchers with a powerful tool to investigate the effectiveness and safety of GLP-1 agonists in diverse populations.The GLP-1 agonist dataset is one of many therapeutic area-specific Virtual Registries within the Helix Research Network. Other registries focus on cardiometabolic diseases, autoimmune conditions, neurodegeneration, and more.Key features of the GLP-1 Agonist Virtual Registry include:Large Cohort: Includes data from over 15,000 patients treated with GLP-1 agonists.Includes data from over 15,000 patients treated with GLP-1 agonists. Comprehensive Genomic Data: Features whole exome sequencing data, providing insights into genetic variations that may influence treatment response.Features whole exome sequencing data, providing insights into genetic variations that may influence treatment response. Longitudinal EHR Data: Includes demographics, clinical diagnoses (type 2 diabetes, cardiovascular disease, kidney disease, etc.), lab results, procedures, and medical and mortality claims data.Includes demographics, clinical diagnoses (type 2 diabetes, cardiovascular disease, kidney disease, etc.), lab results, procedures, and medical and mortality claims data. Regularly Refreshed: The dataset is continuously updated with new information, ensuring researchers have access to the latest insights.“The success of GLP-1 agonists like semaglutide and tirzepatide have created incredible advances in the treatment of cardiometabolic disease and obesity, and the demand for and uptake of these therapies are not slowing down anytime soon,” said James Lu, M.D., Ph.D., CEO of Helix

The Helix Research Network Adds 3 New Health System Members. by Fred Pennic 01/16/2025 Leave a Comment. What You Should Know: – Helix, a population genomics and precision health company, announced a significant expansion of its research network with the addition of three prominent health systems: TriHealth, Parkview Health, and Rochester Regional Health. – Each system has committed to enrolling 100,000 participants, bringing the total number of participants in the Helix Research Network to over 300,000, making it the largest and fastest-growing precision clinical research network globally.Democratizing Access to GenomicsThrough their collaboration with Helix, TriHealth, Parkview Health, and Rochester Regional Health are committed to offering genomics services to their patients, regardless of socioeconomic background. Participation in the research network is voluntary and provided at no cost to individuals.Participants will receive valuable clinical insights about their genetic predispositions to various health conditions, including inherited cancers and high cholesterol. This information can help individuals make informed decisions about their health management and potentially enable early detection and prevention of diseases

What You Should Know:– Helix, a leader in population genomics and precision health, and Komodo Health, a leader in healthcare technology and data-driven insights, are partnering to further enrich Helix’s clinico-genomic datasets within the Helix Research Network (HRN) for research and life science partners.– The partnership will add insights derived from medical, pharmacy and mortality data from Komodo’s Healthcare Map®, the industry’s most robust and precise view of longitudinal de-identified patient-level insights.Helix and Komodo Health Partner to Enhance Precision Medicine with Expanded Clinico-Genomic InsightsHelix, the leading organization in population genomics and precision health, is advancing the integration of genomic data into patient care and therapeutic development through a strategic partnership with Komodo Health. By combining Helix’s robust clinico-genomic dataset with Komodo’s Healthcare Map, this collaboration aims to deliver deeper insights into medication usage, treatment adherence, and the total cost of care across diverse conditions.Enhancing Multimodal Data Depth for ResearchThe partnership builds on Helix’s growing Human Research Network (HRN), a dynamic and continuously expanding clinico-genomic registry. Key features include:   •       Extensive Genomic Profiles: A repository of 500,000 whole-exome profiles, with a target to exceed 1.5 million participants from existing health system partnerships by the end of 2025.   •       Data Integration: Regular electronic health record (EHR) updates across cohorts and the ability to recontact participants for future research opportunities.   •       Multimodal Insights: Integration of Komodo’s data to explore patient responses to treatments and develop targeted profiles for therapeutic innovation.HRN’s clinico-genomic database, already the largest hereditary genomic dataset in North America, is on track to become the largest globally by late 2025. Its dynamic design goes beyond static biobank databases by incorporating real-time updates and longitudinal data, offering researchers unparalleled depth and scope.Empowering Drug Development and Precision MedicineThrough this collaboration, life sciences researchers gain access to actionable insights that inform all stages of the drug development lifecycle. The combined datasets enable a better understanding of treatment outcomes, optimized therapeutic development, and enhanced precision in targeted patient care.Dr. James Lu, CEO and co-founder of Helix, emphasized the partnership’s significance: “Augmenting Helix data with Komodo’s Healthcare Map expands our ability to provide researchers with critical insights into treatment patterns and outcomes